asp isotopes inc - ASPI

ASPI

Close Chg Chg %
7.78 0.33 4.18%

Open Market

8.11

+0.33 (4.18%)

Volume: 5.39M

Last Updated:

Jun 1, 2026, 2:32 PM EDT

Company Overview: asp isotopes inc - ASPI

ASPI Key Data

Open

$7.63

Day Range

7.46 - 8.11

52 Week Range

3.92 - 14.49

Market Cap

$979.53M

Shares Outstanding

125.90M

Public Float

112.95M

Beta

3.43

Rev. Per Employee

N/A

P/E Ratio

N/A

EPS

-$2.07

Yield

0.00%

Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

5.39M

 

ASPI Performance

1 Week
 
40.18%
 
1 Month
 
51.07%
 
3 Months
 
45.69%
 
1 Year
 
2.91%
 
5 Years
 
N/A
 

ASPI Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 3
Full Ratings ➔

About asp isotopes inc - ASPI

ASP Isotopes, Inc. is developing a differentiated isotope enrichment platform to strengthen global supply chain access to critical materials used in nuclear medicine, next-generation semiconductors, and nuclear energy. It operates through the following segments: Nuclear Fuels, Specialist Isotopes and Related Services, and Helium and LNG. The Nuclear Fuels segment engages in the research and development of technologies and methods for producing HALEU and Lithium-6 for the advanced nuclear fuels target market, including the operations of QLE. The Specialist Isotopes and Related Services segment engages in the research and development of technologies and methods for the separation of high-value, low-volume isotopes. The company was founded by Paul E. Mann and Robert Ainscow on September 13, 2021 and is headquartered in Dallas, TX.

ASPI At a Glance

ASP Isotopes, Inc.
2200 Ross Avenue
Dallas, Texas 75201
Phone 1-202-432-8219 Revenue 23.85M
Industry Pharmaceuticals: Major Net Income -175,092,000.00
Sector Health Technology 2025 Sales Growth 475.475%
Fiscal Year-end 12 / 2026 Employees 271
View SEC Filings

ASPI Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 18.622
Price to Book Ratio 2.927
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.974
Enterprise Value to Sales 16.165
Total Debt to Enterprise Value 0.56

ASPI Efficiency

Revenue/Employee 88,003.69
Income Per Employee -646,095.941
Receivables Turnover 0.461
Total Asset Turnover 0.078

ASPI Liquidity

Current Ratio 12.177
Quick Ratio 11.917
Cash Ratio 10.194

ASPI Profitability

Gross Margin 6.26
Operating Margin -239.805
Pretax Margin -669.047
Net Margin -734.169
Return on Assets -57.129
Return on Equity -138.935
Return on Total Capital -41.678
Return on Invested Capital -71.394

ASPI Capital Structure

Total Debt to Total Equity 105.784
Total Debt to Total Capital 51.405
Total Debt to Total Assets 42.107
Long-Term Debt to Equity 99.105
Long-Term Debt to Total Capital 48.16
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Asp Isotopes Inc - ASPI

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
- 433.03K 4.14M 23.85M
Sales Growth
- - +857.04% +475.48%
-
Cost of Goods Sold (COGS) incl D&A
72.57K 294.06K 2.54M 22.36M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
72.57K 37.43K 471.42K 1.91M
Depreciation
72.57K 37.43K 471.42K 1.71M
Amortization of Intangibles
- - - 200.00K
-
COGS Growth
+274.54% +305.20% +765.35% +778.56%
Gross Income
(72.57K) 138.97K 1.60M 1.49M
Gross Income Growth
-274.54% +291.50% +1,051.05% -6.66%
Gross Profit Margin
- +32.09% +38.60% +6.26%
2022 2023 2024 2025 5-year trend
SG&A Expense
5.03M 16.18M 27.95M 58.68M
Research & Development
1.27M 764.58K 3.14M 12.36M
Other SG&A
3.75M 15.42M 24.81M 46.33M
SGA Growth
+94.17% +221.91% +72.75% +109.94%
Other Operating Expense
- - - -
-
Unusual Expense
(150.53K) 194.54K 7.01M 108.63M
EBIT after Unusual Expense
(4.95M) (16.24M) (33.36M) (165.82M)
Non Operating Income/Expense
3.38K 54.82K 1.31M 6.83M
Non-Operating Interest Income
3.38K 9.07K 1.24M 6.79M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
- 118.55K 258.87K 575.00K
Interest Expense Growth
- - +118.37% +122.12%
-
Gross Interest Expense
- 118.55K 258.87K 575.00K
Interest Capitalized
- - - -
-
Pretax Income
(4.95M) (16.30M) (32.31M) (159.56M)
Pretax Income Growth
-89.62% -229.62% -98.23% -393.82%
Pretax Margin
- -3,764.27% -779.67% -669.05%
Income Tax
- (6.13K) 111.45K 282.00K
Income Tax - Current - Domestic
- - - 61.74K
-
Income Tax - Current - Foreign
- - 193.04K 237.00K
-
Income Tax - Deferred - Domestic
- - - -
-
Income Tax - Deferred - Foreign
- - (143.33K) 45.00K
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(4.95M) (16.29M) (32.42M) (159.84M)
Minority Interest Expense
- (7.89K) (89.15K) 15.25M
Net Income
(4.95M) (16.29M) (32.33M) (175.09M)
Net Income Growth
-89.62% -229.34% -98.53% -441.52%
Net Margin Growth
- -3,761.03% -780.21% -734.17%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(4.95M) (16.29M) (32.33M) (175.09M)
Preferred Dividends
- - - 2.78M
-
Net Income Available to Common
(4.95M) (16.29M) (35.11M) (175.09M)
EPS (Basic)
-0.1377 -0.4925 -0.6307 -2.1092
EPS (Basic) Growth
-81.42% -257.66% -28.06% -234.42%
Basic Shares Outstanding
35.91M 33.07M 55.67M 83.01M
EPS (Diluted)
-0.1377 -0.4925 -0.6307 -2.1092
EPS (Diluted) Growth
-81.42% -257.66% -28.06% -234.42%
Diluted Shares Outstanding
35.91M 33.07M 55.67M 83.01M
EBITDA
(5.03M) (16.00M) (25.88M) (55.28M)
EBITDA Growth
-94.17% -218.41% -61.72% -113.58%
EBITDA Margin
- -3,695.98% -624.54% -231.79%

Snapshot

Average Recommendation BUY Average Target Price 12.00
Number of Ratings 3 Current Quarters Estimate -0.273
FY Report Date 06 / 2026 Current Year's Estimate -1.063
Last Quarter’s Earnings -0.14 Median PE on CY Estimate N/A
Year Ago Earnings -2.11 Next Fiscal Year Estimate -1.047
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 3 3 3 3
Mean Estimate -0.27 -0.26 -1.06 -1.05
High Estimates -0.07 -0.06 -0.23 0.01
Low Estimate -0.61 -0.59 -2.40 -2.70
Coefficient of Variance -107.43 -108.50 -109.96 -138.55

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 3 3 2
OVERWEIGHT 0 0 0
HOLD 0 0 0
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Buy Buy Buy

Asp Isotopes Inc in the News